BOSTON, Nov. 6 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. is pleased to announce that the Company has received a significant purchase order for laparoscopic instruments from the St. Mary's Hospital in Waterbury, CT. St. Mary's has been a client of Solos Endoscopy's for over 19 yrs and it has chosen to continue using the Company's surgical products.
Saint Mary's Hospital has played a vital role in the history of Greater Waterbury, providing nearly a century of service to the people of the Central Naugatuck Valley. Founded in 1907 by the Sisters of Saint Joseph of Chambery, Saint Mary's has been a beacon of healing and hope in Waterbury, Connecticut for more than 90 years. The hospital continues to expand its network of services, forging alliances with other key health care providers, and exploring new ways to comfort and cure.
"We are pleased to have St. Mary's remain a client of Solos Endoscopy for so long. We believe this truly validates our surgical products as some of the best on the market. As the Company looks toward the New Year, we will continue to grow our client base and maintain our business relationships with all our clients," stated Bob Segersten, President of Solos Endoscopy, Inc.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
CONTACT: Investor Relations for Solos Endoscopy, Inc., +1-866-THE-APPL(E)
Web site: http://www.solosendoscopy.com/
